Management of Sleep Disturbances Associated with Smith-Magenis Syndrome.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
5
6
2020
medline:
19
8
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
Smith-Magenis syndrome is a genetic disorder caused by a microdeletion involving the retinoic acid-induced 1 (RAI1) gene that maps on the short arm of chromosome 17p11.2 or a pathogenic mutation of RAI1. Smith-Magenis syndrome affects patients through numerous congenital anomalies, intellectual disabilities, behavioral challenges, and sleep disturbances. The sleep abnormalities associated with Smith-Magenis syndrome can include frequent nocturnal arousals, early morning awakenings, and sleep attacks during the day. The sleep problems associated with Smith-Magenis syndrome are attributed to haploinsufficiency of the RAI1 gene. One consequence of reduced function of RAI1, and characteristic of Smith-Magenis syndrome, is an inversion of melatonin secretion resulting in a diurnal rather than nocturnal pattern. Treatment of sleep problems in people with Smith-Magenis syndrome generally involves a combination of sleep hygiene techniques, supplemental melatonin, and/or other medications, such as melatonin receptor agonists, β
Identifiants
pubmed: 32495322
doi: 10.1007/s40263-020-00733-5
pii: 10.1007/s40263-020-00733-5
doi:
Substances chimiques
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM